Register Login
Register to leave comments
  • News bot Sept. 3, 2025, 3:14 p.m.

    📋 BridgeBio Pharma, Inc. (BBIO) - financial_results

    Filing Date: 2022-05-10

    Accepted: 2022-05-10 17:24:00

    Event Type: financial_results

    Event Details:

    BridgeBio Pharma, Inc. (BBIO) Reports {period} Financial Results BridgeBio Pharma, Inc. (BBIO) announced its financial results for the period ending 2022-05-05. Key Financial Highlights:
    • Revenue: 1694
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 633454
    No specific business highlights were provided.
    • anticipated in mid-2022
    • anticipated in second half of 2022
    • expected in mid-2023

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Revenue 1.69K 462.00 $1.23K +266.67%
    Operating Costs and Expenses: Operating Costs And Expenses Research Development 109.00K 122.56K $-13.56K -11.07%
    Operating Costs and Expenses: Operating Costs And Expenses Selling General Administrative 43.71K 45.41K $-1.69K -3.73%
    Total Operating Expenses 175.37K 167.97K $7.41K +4.41%
    Loss From Operations 173.68K 167.50K $6.17K +3.69%
    Other Income/(Expense), Net: Other Income Expense Net Interest Income 267.00 394.00 $-127.00 -32.23%
    Other Income/(Expense), Net: Other Income Expense Net Interest Expense 20.34K 9.74K $10.61K +108.91%
    Other Income/(Expense), Net: Other Income Expense Net Other Income Net 7.58K 5.77K $1.81K +31.37%
    Total Other Income Expense 27.65K 3.58K $24.07K +672.83%
    Net: Loss 201.33K 171.08K $30.25K +17.68%
    Net: Loss Attributable Noncontrolling 4.93K 8.00K $-3.07K -38.36%
    Net: Loss Attributable Common Stockholders 196.40K 163.08K $33.32K +20.43%
    Net Loss Per Share 1.35 1.18 $0.17 +14.41%
    Weighted Average Shares 145.88M 138.63M $7.25M +5.23%
    Research Development 8.56K 22.45K $-13.89K -61.88%
    Selling General Administrative 14.55K 12.45K $2.10K +16.91%
    Assets: Cash Equivalents Marketable Securities 633.45K 787.51K $-154.06K -19.56%
    Assets: Investment Equity Securities 37.77K 49.15K $-11.38K -23.15%
    Assets: Receivable Licensing Collaboration 10.98K 19.75K $-8.77K -44.39%
    Assets: Prepaid Expenses Other Current 34.02K 32.45K $1.57K +4.85%
    Assets: Property Equipment Net 17.18K 30.07K $-12.88K -42.85%
    Assets: Operating Lease Right Of Use 13.94K 15.91K $-1.97K -12.39%
    Assets: Intangible Net 30.48K 44.93K $-14.46K -32.18%
    Assets: Other 35.33K 33.03K $2.30K +6.96%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Accounts Payable 10.11K 11.88K $-1.78K -14.95%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Accrued Liabilities 88.99K 118.25K $-29.25K -24.74%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Operating Lease Liabilities 19.86K 22.37K $-2.51K -11.22%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Notes 733.58K 733.12K $462.00 +0.06%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Notes 540.36K 539.93K $421.00 +0.08%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Term Loans 434.11K 430.75K $3.36K +0.78%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Other Long Term Liabilities 26.83K 22.07K $4.76K +21.57%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Redeemable Convertible Noncontrolling Interests 336.00 1.42K $-1.09K -76.39%
    Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders Deficit: Liabilities Redeemable Convertible Noncontrolling Interests And Stockholders Deficit Noncontrolling Interests 27.00 3.41K $-3.38K -99.21%

    Structured Data:

    • Company Name: BridgeBio Pharma, Inc.
    • CIK: 0001743881
    • Ticker Symbol: BBIO
    • Period End Date: 2022-05-05
    • Document Type: 8-K

    🔬 Clinical Development Pipeline (BridgeBio Pharma, Inc.):

    Therapeutic Focus Areas:
    • Cardiology
    • Oncology
    • Muscular Dystrophy
    • Rare Diseases
    Clinical Trials by Phase:
    • Phase 2 trials ongoing
    • Phase 3 trials ongoing
    Upcoming Milestones:
    • Trial Initiation: 2022
    • Study Completion: 2024
    • Study Completion: 2022
    • Study Completion: 2022
    • Data Expected: 2023
    • Data Expected: 2041
    Recent Developments:
    • Positive results reported

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval

Search

News categories